



# Balfour Capital Group HCA Healthcare, Inc.

HCA Healthcare is a leading U.S.-based for-profit healthcare provider headquartered in Nashville, Tennessee. The company operates 186 hospitals and approximately 2,400 ambulatory care sites—including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics—across 20 U.S. states and the United Kingdom. HCA focuses on delivering integrated, patient-centered care with an emphasis on quality and efficiency.

## 1. Top 5 Competitors

Based on industry comparisons, HCA's primary competitors include:

1. Tenet Healthcare (THC)
2. Universal Health Services (UHS)
3. Encompass Health (EHC)
4. Community Health Systems (CYH)
5. Ascension Health

These companies operate in the health care facilities sector and offer similar services.

## 2. Largest Institutional Shareholders

As of the latest filings, the top institutional holders of HCA include:

- Vanguard Group Inc. – \$4.75B
- BlackRock Inc. – \$4.52B
- Sanders Capital LLC – \$3.50B
- State Street Corp. – \$3.38B
- Wellington Management Group LLP – \$1.94B

## 3. Management Team

Key executives at HCA Healthcare include:

- Samuel N. Hazen – Chief Executive Officer
- William B. Rutherford – Executive Vice President & Chief Financial Officer
- Jennifer Berres – Senior Vice President & Chief Human Resources Officer
- Michael Cuffe, MD – Executive Vice President & Chief Clinical Officer



# Balfour Capital Group HCA Healthcare, Inc.

## 4. Revenue

HCA reported the following revenues:

- Full Year 2024: \$70.6 billion
- Q1 2025: \$18.32 billion, a 5.7% increase year-over-year

The company projects full-year 2025 revenue between \$72.8 billion and \$75.8 billion.

## 5. Institutions with Buy Recommendations:

Recent analyst actions include:

- Mizuho maintained a "Buy" rating as of July 2023.
- Guggenheim initiated coverage with a "Neutral" rating in April 2025.

## 6. Summary of Analyst Sentiment:

Analysts have a generally positive outlook on HCA:

- Zacks Investment Research upgraded HCA to a "Strong Buy" in late 2024.

MarketGrader assigned a sentiment score of 8.1/10, indicating positive sentiment.

However, some concerns have been raised regarding staffing levels and patient care quality following certain acquisitions.

## 7. Insider Buying and Selling (Last 24 Months)

Over the past two years:

- Shares Sold: 70,389 shares, totaling approximately \$22.97 million.

In the last quarter:

- Shares Bought: 185,500 shares, valued at \$58.6 million.
- Shares Sold: 39,000 shares, totaling \$12.6 million.